• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

花粉形状药物载体在干粉吸入中的可行性研究。

Feasibility study of pollen-shape drug carriers in dry powder inhalation.

机构信息

School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore, Singapore.

出版信息

J Pharm Sci. 2010 Mar;99(3):1309-21. doi: 10.1002/jps.21913.

DOI:10.1002/jps.21913
PMID:19862802
Abstract

The feasibility of using pollen-shape carriers in dry powder inhalation is studied. Pollen-shape hydroxyapatite (HA) particles are synthesized with a geometric diameter range from 21.1 to 48.6 microm and effective density range from 0.21 to 0.41 g/cm(3). The flowability of the particles is characterized by the Carr's compressibility index (CI) and angle of slide (theta). The HA carriers are found to have better flowability than commonly used lactose (LA) carrier with similar size range. The HA carriers are also found to be capable of high drug attachment. The aerosolization and deposition properties of a model drug are compared using HA and LA as carriers. Results indicate that pollen-shape HA carriers have good potential to be used as drug carrier in dry powder inhalation. It can give higher drug emission and respirable fraction than traditional LA carriers.

摘要

研究了花粉形状载体在干粉吸入中的可行性。合成了具有从 21.1 到 48.6 微米的几何直径范围和从 0.21 到 0.41 克/厘米 3 的有效密度范围的花粉形状羟基磷灰石(HA)颗粒。通过 Carr 可压缩性指数(CI)和滑动角(theta)来表征颗粒的流动性。发现与具有相似粒径范围的常用乳糖(LA)载体相比,HA 载体具有更好的流动性。还发现 HA 载体能够实现高药物附着。使用 HA 和 LA 作为载体比较了模型药物的气溶胶化和沉积特性。结果表明,花粉形状的 HA 载体具有作为干粉吸入用药物载体的良好潜力。它可以比传统的 LA 载体产生更高的药物释放和可吸入分数。

相似文献

1
Feasibility study of pollen-shape drug carriers in dry powder inhalation.花粉形状药物载体在干粉吸入中的可行性研究。
J Pharm Sci. 2010 Mar;99(3):1309-21. doi: 10.1002/jps.21913.
2
Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.不同药物混合比例干粉制剂中花粉状载体的吸入性能:与乳糖载体的比较。
Int J Pharm. 2010 Feb 15;386(1-2):6-14. doi: 10.1016/j.ijpharm.2009.10.047. Epub 2009 Nov 14.
3
Inhalation performance of pollen-shape carrier in dry powder formulation: effect of size and surface morphology.干粉制剂中花粉状载体的吸入性能:粒径和表面形态的影响。
Int J Pharm. 2011 Jul 15;413(1-2):93-102. doi: 10.1016/j.ijpharm.2011.04.033. Epub 2011 Apr 21.
4
Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.乳糖作为干粉制剂中的载体:表面特性对药物递送的影响。
J Pharm Sci. 2001 Sep;90(9):1424-34. doi: 10.1002/jps.1094.
5
Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.干粉吸入器:含有硫酸沙丁胺醇的乳糖配方的机械评估。
Int J Pharm. 2012 Feb 28;423(2):184-94. doi: 10.1016/j.ijpharm.2011.12.018. Epub 2011 Dec 17.
6
Effect of particle shape on dry particle inhalation: study of flowability, aerosolization, and deposition properties.颗粒形状对干粉吸入的影响:流动性、气溶胶化和沉积特性的研究。
AAPS PharmSciTech. 2009;10(4):1252-62. doi: 10.1208/s12249-009-9313-3. Epub 2009 Oct 29.
7
[Recent progress of dry powder inhalation of proteins and peptides].[蛋白质和肽类干粉吸入剂的研究进展]
Yao Xue Xue Bao. 2015 Jul;50(7):814-23.
8
Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.乳糖载体颗粒的表面处理对硫酸沙丁胺醇干粉吸入特性的影响。
Chem Pharm Bull (Tokyo). 2004 Aug;52(8):938-42. doi: 10.1248/cpb.52.938.
9
Pulmonary deposition of lactose carriers used in inhalation powders.吸入粉雾剂中乳糖载体的肺部沉积。
Int J Pharm. 2000 Feb 25;196(1):95-103. doi: 10.1016/s0378-5173(99)00450-0.
10
Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.乳糖载体颗粒表面包覆对硫酸沙丁胺醇干粉吸入特性的影响。
Chem Pharm Bull (Tokyo). 2003 Dec;51(12):1455-7. doi: 10.1248/cpb.51.1455.

引用本文的文献

1
Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.干粉吸入器中使用的不同载体:其颗粒特性
J Aerosol Med Pulm Drug Deliv. 2024 Dec;37(6):307-327. doi: 10.1089/jamp.2023.0029. Epub 2024 Aug 9.
2
PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).载前列腺素 E1-羟丙基-β-环糊精(PGE1-HPβCD)复合物的 PLGA 微球用于治疗肺动脉高压(PAH)。
Pharm Res. 2011 Jul;28(7):1733-49. doi: 10.1007/s11095-011-0409-6. Epub 2011 Apr 6.